Drug discovery and development – Page 31
-
FeatureChemistry in bloom
Sarah Houlton discovers the chemistry among the specimens at many botanical gardens
-
ResearchCoated nanoparticles show Alzheimer's promise
Gold nanoparticles functionalised with amino acid polymer inhibit the growth of amyloid fibres associated with neurodegenerative disease
-
ResearchAntimalarial flow synthesis closer to commercialisation
Scientists in Germany hope their continuous flow method will boost accessibility of artemisinin-derived medicines
-
ResearchBringing chemical synthesis to the masses
Researchers hope simple system to build thousands of peptides without enzymes, cells or reagents will be accessible to all
-
Business
Piramal exits drug discovery in India
Company will concentrate on generic medicines and clinical and contract research.
-
ResearchFluorinating new life into an increasingly ineffective antibiotic
Aminoglycoside analogue evades bacterial resistance mechanism
-
Research
Ionic liquids join battle against antibiotic resistance
Organic salts disrupt biofilms to leave resistant bacteria at the mercy of antibiotics
-
NewsDoctors turn to experimental Ebola treatments
Drugs and vaccines untested in humans are being trialled on Ebola patients
-
Business
Single shot antibiotic approved for skin infections
Third drug in three months approved under US antimicrobials incentive scheme
-
NewsCall for new models to pay for antibiotics
UK government report on ways to fight resistance follows prime minister’s call for global action
-
NewsRenewed focus on dementia checked by drug challenges
‘Ticking time bomb’ of global neurodegenerative disease burden will be difficult to defuse
-
-
NewsChina gets tough with polluters
Amendments to country’s 25-year-old environment law paves the way for unlimited fines for environmental damage
-
CareersRemote possibilities
Now you can graduate in drug discovery without ever leaving the house, as Sarah Houlton finds out
-
ResearchDual warhead kills and disarms bacteria
Compound damages bacterial membrane and disables resistance mechanism in a two-pronged attack
-
-
OpinionEngineering serendipity
It takes more than random stumbling to find new reactions, says Derek Lowe
-
Business$25bn-plus trade sharpens pharma giants’ focus
Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process
-
FeatureTargeting breast cancer
Tamoxifen has been treating breast cancer for 40 years, but few would have predicted how much this drug would contribute to saving lives, writes John Mann
-
OpinionKnown unknowns
New molecules with unpredictable biological activity deserve sensible amounts of respect, says Derek Lowe